Multicenter Study to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Single Tooth Restorations

Jaw, Edentulous, Partially Clinical Trial

Official title:

An Open, Prospective, Multicenter Investigation to Evaluate the Clinical Outcome of PrimeTaper EV Implant in Extraction Sockets and Healed Ridges - A 5 Year Follow-up

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05315414
• Other study ID #: C-PT-21-001
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 3, 2022
• Est. completion date: May 2029

Study information

• Verified date: June 2024
• Source: Dentsply Sirona Implants and Consumables
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the clinical outcome of implant survival of the PrimeTaper EV implant in single tooth restorations 1 year after permanent restoration.

Other known NCT identifiers

• NCT05387421

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 138
• Est. completion date: May 2029
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adult aged 18-75 years.

• Willing and able to sign and date the informed consent form.

• In need of an implant in position 16 to 26 or 36 to 46, and each subject can only receive one implant.

• Deemed by the investigator as likely to present with an initially stable implant situation.

• A stable occlusion, i.e. an opposing natural dentition, a crown, an implant-supported fixed or removable prosthesis, a partial removable prosthesis or a full denture.

• An adjacent tooth (root with natural or artificial crown) or an implant-supported crown mesially and distally. Exemption: If the planned implant is in the first molar position, an edentulous space is accepted distally

Exclusion Criteria:

• Not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.

• Unlikely to be able to comply with clinical investigation procedures according to investigator's judgement.

• Unable or unwilling to return for follow-up visits for a period of 5 years.

• Known allergy or hypersensitivity to titanium and/or stainless steel.

• Uncontrolled pathological process in the oral cavity, e.g. untreated rampant caries and uncontrolled periodontal disease.

• Uncontrolled para-functional habits, e.g. bruxism.

• Current need of any Guided Bone Regeneration (GBR) procedure in the planned implant area (gap filling at immediate placement and soft tissue grafting are allowed).

• Systemic or local disease or condition that would compromise post-operative healing and/ or osseointegration.

• Immunosuppression, use of corticosteroids, per-os or intravenous bisphosphonate use, or any other medication such as anti-resorptive therapy or monoclonal antibodies that could compromise post-operative healing and/or osseointegration.

• Any other condition that would make the subject unsuitable for participation, including but not limited to;

• History of radiation therapy in the head and neck region.

• History of chemotherapy within 5 years prior to surgery.

• Present alcohol and/or drug abuse.

• Ongoing psychiatric illness.

• Current smoking/use of tobacco, including e-cigarettes.

• Any ongoing disease that would make the subject unsuitable for participation, including but not limited to;

• Recent myocardial infarction (< 3 months*).

• Recent cerebrovascular accident (< 3 months*).

• Recent cardiac-valvular prosthesis placement (< 3 months*).

• Hemorrhagic diathesis.

• Severe liver dysfunction.

• Known or suspected current malignancy.

• Uncontrolled diabetes mellitus.

• Florid infection.

• Pregnant or breastfeeding females. (Pregnancy tests will be performed as per local requirements).

• Previous enrolment in the present clinical investigation.

• Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona staff and the clinical investigation site).

• Simultaneous participation in another clinical investigation, or participation in a clinical investigation during the last 6 months that may interfere with the present clinical investigation.

• < 3 months is a strict exclusion criterion. After 3 month it is up to the investigator to judge whether the subject is considered suitable for participation or not.

Related Conditions & MeSH terms

• Jaw, Edentulous
• Jaw, Edentulous, Partially

Intervention

Device:
• PrimeTaper EV implant
Tapered dental implant developed by Dentsply Sirona

Locations

Country	Name	City	State
Belgium	Catholic University of Leuven	Leuven
Germany	Dental practice Dr Mischa Krebs	Alzey
Italy	Studio Toia	Busto Arsizio
Netherlands	Dr.F.L.Guljé, De Mondhoek	Apeldoorn
United States	University of Iowa	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Dentsply Sirona Implants and Consumables

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Italy,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implant survival, i.e. number of implants in place counted clinically, 1 year after permanent restoration.	Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.	One year post permanent restoration (anticipated average 3 months after implant placement).
Secondary	Implant survival, i.e. number of implants in place counted clinically, 2, 3, 4 and 5 years after permanent restoration.	Implant survival rate is a binary variable evaluated clinically, i.e. 'Yes' or 'No' where 'Yes' means that the implant is still in place and 'No' means that the implant is not in place. Any implant that has been removed or lost after implant placement visit will be considered a failure, whatever the reason for removal/loss.	2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Secondary	Change of implant stability quotient value (ISQ) between implant placement and permanent restoration.	Implant stability will be evaluated through ISQ value using Resonance Frequency Analysis (RFA). The stability is presented as an ISQ value. The higher the ISQ value the higher the stability. Recorded as a numeric value (1-100).	From date of implant placement (anticipated average 1 month after inclusion) to date of permanent restoration (anticipated average 3 months after implant placement).
Secondary	Maximum insertion torque value for each implant at implant placement.	Maximum insertion torque value (ITV), based on ITV curve, measured in Ncm.	At date of implant placement (anticipated average 1 month after inclusion).
Secondary	Final insertion torque value for each implant at implant placement.	Final insertion torque value (ITV), based on ITV curve, measured in Ncm.	At date of implant placement (anticipated average 1 month after inclusion).
Secondary	Investigator questionnaire for each investigational medical device after implant placement.	Numerical scale 1-10, where 1 = totally disagree with the statement, and 10 = totally agree with the statement. Statements to be evaluated by the surgeon: "The implant was guided into the prepared osteotomy", "The implant followed the prepared osteotomy", "The implant has a good primary stability", "The drilling protocol is easy to use", "The implant has efficient cutting properties". Each statement will be evaluated separately.	Immediately after implant placement (anticipated average 1 month after inclusion).
Secondary	Implant success, i.e., number of implants documented as successful at 1, 2, 3 and 5 years after permanent restoration.	Successful implants counted, i.e. 'Yes' or 'No'. An implant will be considered successful if all of the following criteria are fulfilled: Implant in place.; Lack of evidence of peri-implant radiolucency in X-ray.; Less than 1mm vertical bone loss during first year after loading with permanent restoration and 0,2mm annually thereafter.; Absence of persistent and/or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or violation of the mandibular canal.	1, 2, 3 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Secondary	Change of marginal bone level up to 5 years post permanent restoration compared to permanent restoration.	MBL changes determined from radiographs, expressed as the distance from the implant reference point to the most coronal bone-to-implant contact on the mesial and distal side of the implant. The average will be calculated and compared for each evaluation period.	At permanent restoration (anticipated average 3 months after implant placement) and 1, 2, 3 and 5 years post permanent restoration.
Secondary	Change of probing pocket depth (PPD) in mm between permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.	Probing Pocket Depth (PPD) measured as the distance from the mucosal margin to the bottom of the probe-able pocket in mm.	At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Secondary	Presence of bleeding on probing (BoP), at permanent restoration, and 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.	Bleeding on Probing (BoP) recorded as presence or absence of bleeding when probing to the bottom of the pocket.	At permanent restoration (anticipated average 3 months after implant placement) and 6 months, 1, 2, 3, 4 and 5 years post permanent restoration.
Secondary	Presence of plaque at 6 months, 1, 2, 3, 4 and 5 years after permanent restoration.	Plaque recorded as presence or absence of plaque by visual inspection on four surfaces at each implant site.	6 months, 1, 2, 3, 4 and 5 years post permanent restoration (anticipated average 3 months after implant placement).
Secondary	Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies during the clinical investigation.	Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.	Up to 5 years after permanent restoration (anticipated average 3 months after implant placement).